GlassScriptPhysician profile
Mark A Piekarsky
NPI 1558355792
$12,143.21
in general payments reported to CMS, 2019-2025
51 companies · $3,216 in 2025
The $3,216 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,497 · 2020: $356 · 2021: $513 · 2022: $1,741 · 2023: $2,340 · 2024: $2,482 · 2025: $3,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,037.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,249.18 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,202.86 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $998.42 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $961.62 | 2019-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $802.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $801.07 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $753.72 | 2019-2025 | |
| Lilly USA, LLC | $715.33 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.16 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $368.51 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $323.38 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $315.55 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $288.93 | 2022-2025 | Eliquis |
| Exact Sciences Corporation | $286.11 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $281.31 | 2019-2025 | Evenity, Prolia, Otezla |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Piekarsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.